MCHM3001 · From Molecules to Therapeutics
The Complete Exam Bible · S1 2027From Molecules to Therapeutics
MCHM3001 From Molecules to Therapeutics is the University of Sydney's third-year medicinal-chemistry unit (dual-coded with the advanced MCHM3901), taught jointly by the School of Medical Sciences and the School of Chemistry, and it walks the whole drug-discovery pipeline from target to market. The University of Sydney structures MCHM3001 around three themes — target identification and hit discovery (omics, the druggable proteome, cell models, antibodies, high-throughput and display screening), optimising target interactions (in-silico design, hit-to-lead synthesis, lead optimisation and ADME) and getting the drug to market (economics, clinical trials, imaging agents, toxicology and TGA regulation). It is a method-and-reasoning subject: the marks live in naming the right stage or model, applying the taught relationship (IC50, the Z-factor, Lipinski's rule of 5, the Tanimoto coefficient, percentage ionisation, exposure ratios), and interpreting the result. Assessment runs through Canvas as continuous coursework — a 10% lay presentation, a 10% group TGA-approval presentation, a 10% in-silico docking figure, two in-person tests worth 5% each, a 16% fragment-based-drug-design practical project and lab report, and small safety quizzes — capped by a comprehensive final exam worth 40% of the unit. The unit provides no sample or past exam paper and lists the exam format as 'to be advised', so this guide fills that gap by teaching the examinable method across every stage of the pipeline; the MCHM3001 result also feeds the Weighted Average Mark (WAM) that later units build on.
What MCHM3001 covers
MCHM3001 From Molecules to Therapeutics runs across three teaching themes — target identification and hit discovery, optimising target interactions, and getting the drug to market — and this thirteen-chapter map follows the lecture schedule through all three. The unit is assessed by continuous coursework (a lay presentation, a group TGA presentation, an in-silico docking figure, two in-person tests and a fragment-based-drug-design practical project and lab report) plus a comprehensive final exam worth 40% of the unit. Use the map to see how each week's method builds toward that final.
How MCHM3001 is assessed
| Component | Weight | Format |
|---|---|---|
| Final Exam | 40% | USyd S1 exam period; format 'to be advised' (no sample paper provided) — confirm on the unit outline |
| Practical Project & Lab Report | 16% | Individual; fragment-based drug design on MMP-3 (IC50 etc.), LabArchives e-notebook |
| Lay Presentation ('A Drug Discovery Story') | 10% | Individual live oral + written text, ~Week 3 |
| Group Presentation: Drug Approval by the TGA | 10% | Group slide presentation, ~Week 6 |
| In-Silico Docking Assignment | 10% | Group; a docking figure + legend (<=200 words), ~Week 7 |
| Test 1 + Test 2 | 5% + 5% | In-person paper-based, 70 min each (incl. reading), ~Weeks 4 and 9 |
| Chemistry Safety Quiz + HIRACs | 2% + 2% | Online safety quiz + hazard/risk assessment, early semester |
IC50 of a fragment-derived lead against MMP-3
- +1Define IC50 on this plot. IC50 is the inhibitor concentration that reduces activity to 50% of the control, so set y = 50 in the fitted line y = −40x + 70.
- +1Solve for x (= log₁₀[inhibitor]): 50 = −40x + 70 → 40x = 70 − 50 = 20 → x = 20/40 = 0.5.
- +1Back-transform from the log axis: [inhibitor] = 10^x = 10^0.5 = 3.16 µM (the x-axis was log₁₀ of the molar concentration expressed in µM units for the plot).
- +1State the exclusion rule taught for the fit: discard points below 10% and above 90% control activity — near-total or near-zero inhibition is insensitive to concentration and distorts the linear region; the points nearest 50% carry the most weight.
- +1Interpret: IC50 ≈ 3.2 µM. A fragment-derived lead in the low-micromolar range is a credible starting point; lead optimisation would push it toward the low-nanomolar potency of a developable drug (roughly a 1000-fold gain).
Key terms
- IC50
- The inhibitor concentration that halves a biological or biochemical activity (50% inhibition). It is assay-dependent (relative), quoted in molar units; an optimised drug typically sits in the low-nanomolar range.
- Dissociation constant (KD)
- For A + B ⇌ AB, KD = [A][B]/[AB] = k_off/k_on, in concentration units. When free ligand equals KD, half the protein is bound; a lower KD means higher affinity.
- Lipinski's rule of 5
- A developability filter for oral absorption: MW < 500 Da, H-bond donors < 5, H-bond acceptors < 10, and cLogP < 5; an orally active drug generally has no more than one violation.
- Druggable proteome
- The subset of proteins (~3,000 of the ~20,000 human proteins) that can bind a drug-like small molecule with useful affinity; a drug target must also be disease-linked and disease-modifying.
- Pharmacophore
- The common three-dimensional arrangement of features (H-bond donor/acceptor, hydrophobe, aromatic ring) shared by active molecules, defined by inter-feature distances and angles — the basis of ligand-based design.
- Common Technical Document (CTD)
- The five-module dossier a sponsor submits to a regulator such as the TGA: M1 region-specific admin, M2 summaries, M3 quality/CMC, M4 non-clinical reports, M5 clinical reports.
MCHM3001 FAQ
Is MCHM3001 hard?
It is broad rather than mathematically deep. MCHM3001 marches through the entire drug-discovery pipeline — omics target finding, the druggable proteome, screening, in-silico design, hit-to-lead synthesis, lead optimisation, ADME, imaging, toxicology and TGA regulation — so the real challenge is holding a dozen linked methods and their vocabulary in your head at once. The quantitative parts (IC50, the Z-factor, Lipinski's rule of 5, the Tanimoto coefficient, percentage ionisation, exposure ratios) are algebra and careful units, not hard maths. Students who keep each week's method warm and can explain why a stage exists, rather than cramming names through STUVAC, tend to find it manageable.
Can AI help me with MCHM3001?
Yes, as a step-by-step study aid. Sia is an AI tutor trained on how MCHM3001 is actually taught and assessed: it can walk you through an IC50 or Z-factor calculation line by line, explain why the space of druggable proteins is only a fraction of the proteome, unpack the CYP450 catalytic cycle, or quiz you on the CTD modules — and it checks your reasoning as you go. It explains the method and helps you learn it; it does not do your graded assessment for you, and University of Sydney academic-integrity rules still apply.
Where can I find past exam papers or practice for MCHM3001?
Start on Canvas and in the University of Sydney Library's past-exam-paper collection for anything the unit officially releases — but note that MCHM3001 provides no sample or past exam paper, and the exam format is listed as 'to be advised', so do not expect one. Your two in-person tests, the tutorials and the practical assessments are your closest official practice. This guide fills the gap with worked, exam-style problems across the whole pipeline using fresh numbers, and you can ask Sia to generate more practice in the same style and explain each step.
Does MCHM3001 have a hurdle, and how is it assessed?
The unit is assessed by continuous coursework plus a 40% final exam. The available and official sources do not state a numeric pass-hurdle on the exam, so do not assume one — confirm the current pass rules on Canvas and the unit outline. What is required is participation: attendance at all practicals and workshops is stated as mandatory, and the chemistry safety quiz and HIRAC hazard assessments are gating prerequisites you must complete before the wet-lab pracs. The final exam weight (40%) is confirmed; its format, duration and open- or closed-book status are 'to be advised' — check them on the unit outline.
What is the MCHM3001 final exam like?
It is comprehensive across the whole unit, so expect the recurring examinable methods: naming pipeline stages and target classes, the druggable-versus-target distinction, IC50 and Z-factor reasoning, Lipinski and Veber developability filters, the Tanimoto similarity coefficient, percentage ionisation and logP, the CYP450 catalytic cycle and metabolic-stability tactics, clinical-trial phases, PET/SPECT half-lives, and the CTD/TGA submission. The 40% weight is confirmed; the format and duration are 'to be advised' in the unit materials, so confirm them on Canvas and the University of Sydney exam timetable (the S1 2027 exam period is around June 2027).
How to study for the exam
Treat MCHM3001 as one continuous pipeline rather than 23 separate lectures: for every method, be able to say which stage it belongs to (target ID, hit discovery, optimisation, or market) and why that stage needs it. Each week, work one problem of that week's quantitative method end to end — IC50 from a % control line, a Z-factor from control means and SDs, a Lipinski/Veber violation count, a Tanimoto coefficient, a percentage-ionisation calculation, an exposure ratio, a radio-isotope half-life decay — writing the relationship, substituting with units, and interpreting the number. Because Test 1 and Test 2 sample the first and second halves of the semester, keep earlier methods warm rather than filing them away. For the comprehensive 40% final, prioritise breadth: you should be able to start a question anywhere on the pipeline before you deepen the topics you find hardest. When a step will not click — the CYP catalytic cycle, why only the space-mean of druggability counts, or how deconvolution recovers a hit — ask Sia to re-explain that single step a different way and set you a fresh practice question in the same style; it teaches the method and checks your reasoning, and never substitutes for your own graded work. Confirm the exam date, room and format on Canvas and the University of Sydney exam timetable.
Your AI Chemistry tutor for MCHM3001
Stuck on a hard MCHM3001 question? Sia is AskSia’s AI Chemistry tutor — ask any MCHM3001 From Molecules to Therapeutics question and get a clear, step-by-step explanation grounded in how the course is actually taught and assessed. Read this whole study guide free, then take your hardest questions to Sia.
